Brief: Oncopeptides Q4 Operating Profit SEK -80.98 Million
27/02/2024 07:00
Feb 27 (Reuters) - Oncopeptides Q4 adjusted EPS SEK -0.9. * Q4 adjusted free cash flow SEK -55.395 million * Q4 net income SEK -81.211 million * Q4 sales SEK 5.337 million
Recent news on Oncopeptides AB
See all newsSweden's Oncopeptides Q3 net sales rise on Pepaxti demand
Brief: Oncopeptides Q3 Operating Profit SEK -36.47 Million
Brief: Oncopeptides Completes Directed Share Issue Of SEK 100 Mln
Brief: Oncopeptides Confirms Blood-Brain-Barrier Penetration In Glioblastoma Study
Swedish biotech Oncopeptides' Q2 net sales rise on strong demand in Italy